Vertex Pharmaceuticals (NASDAQ:VRTX)‘s stock had its “buy” rating restated by stock analysts at JPMorgan Chase & Co. in a report issued on Tuesday.

A number of other brokerages also recently weighed in on VRTX. Maxim Group reissued a “buy” rating and set a $195.00 target price on shares of Vertex Pharmaceuticals in a research note on Thursday, October 26th. Royal Bank of Canada started coverage on shares of Vertex Pharmaceuticals in a research note on Thursday, September 14th. They set an “outperform” rating and a $175.00 target price for the company. Zacks Investment Research raised shares of Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $174.00 target price for the company in a research note on Tuesday, September 26th. Deutsche Bank started coverage on shares of Vertex Pharmaceuticals in a research note on Tuesday, December 12th. They set a “buy” rating and a $175.00 target price for the company. Finally, DA Davidson started coverage on shares of Vertex Pharmaceuticals in a research note on Friday, September 29th. They set a “buy” rating and a $200.00 target price for the company. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, twenty-five have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $175.89.

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) traded down $0.93 during midday trading on Tuesday, reaching $155.96. 268,716 shares of the company were exchanged, compared to its average volume of 1,651,560. Vertex Pharmaceuticals has a fifty-two week low of $77.09 and a fifty-two week high of $167.85. The company has a market capitalization of $39,280.00, a P/E ratio of 199.95, a PEG ratio of 1.84 and a beta of 1.58. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.28 and a quick ratio of 3.14.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.49. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The business had revenue of $578.20 million during the quarter, compared to the consensus estimate of $522.07 million. During the same quarter last year, the firm earned $0.16 earnings per share. Vertex Pharmaceuticals’s quarterly revenue was up 39.7% on a year-over-year basis. analysts anticipate that Vertex Pharmaceuticals will post 0.76 earnings per share for the current year.

In other news, COO Ian F. Smith sold 2,125 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $155.61, for a total transaction of $330,671.25. Following the completion of the transaction, the chief operating officer now directly owns 118,013 shares in the company, valued at $18,364,002.93. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Thomas Graney sold 777 shares of Vertex Pharmaceuticals stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $149.95, for a total transaction of $116,511.15. The disclosure for this sale can be found here. Insiders sold 345,586 shares of company stock valued at $49,802,201 over the last 90 days. Corporate insiders own 1.80% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of VRTX. Commerce Bank acquired a new position in shares of Vertex Pharmaceuticals during the second quarter valued at about $206,000. Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of Vertex Pharmaceuticals during the second quarter valued at about $465,000. Schroder Investment Management Group grew its holdings in shares of Vertex Pharmaceuticals by 8.0% during the second quarter. Schroder Investment Management Group now owns 33,398 shares of the pharmaceutical company’s stock valued at $4,250,000 after buying an additional 2,478 shares during the last quarter. Private Advisor Group LLC grew its holdings in shares of Vertex Pharmaceuticals by 2.4% during the second quarter. Private Advisor Group LLC now owns 5,457 shares of the pharmaceutical company’s stock valued at $702,000 after buying an additional 129 shares during the last quarter. Finally, Commonwealth Bank of Australia grew its holdings in shares of Vertex Pharmaceuticals by 5.7% during the second quarter. Commonwealth Bank of Australia now owns 3,532 shares of the pharmaceutical company’s stock valued at $453,000 after buying an additional 190 shares during the last quarter. Hedge funds and other institutional investors own 93.09% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Vertex Pharmaceuticals (VRTX) Given Buy Rating at JPMorgan Chase & Co.” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.watchlistnews.com/vertex-pharmaceuticals-vrtx-given-buy-rating-at-jpmorgan-chase-co/1799849.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Analyst Recommendations for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.